Trials / Completed
CompletedNCT02618967
Single Ascending Dose Study of AMG 570 in Healthy Subjects
A Randomized, Double Blind Placebo Controlled, First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Subcutaneous Doses of AMG 570 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to obtain initial information on the safety and tolerability (effects good or bad), pharmacokinetics (what the body does to the drug), and pharmacodynamics (what the drug does to the body) of a single dose of AMG 570.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AMG 570 | 7 dose levels of AMG 570 administered as single dose subcutaneous in healthy volunteers. |
| BIOLOGICAL | AMG 570 Matching Placebo | Placebo administered as single dose subcutaneous in healthy volunteers. |
Timeline
- Start date
- 2016-03-28
- Primary completion
- 2018-09-06
- Completion
- 2018-12-03
- First posted
- 2015-12-02
- Last updated
- 2024-05-14
- Results posted
- 2021-10-15
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02618967. Inclusion in this directory is not an endorsement.